Bonnie Ky

List of Publications by Year
in descending order

160 papers	11,673 citations	46918 47 h-index	29081 104 g-index
162 all docs	162 docs citations	162 times ranked	11976 citing authors

#	Article	IF	Citations
1	Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 2014, 27, 911-939.	1.2	1,051
2	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 893-911.	0.8	860
3	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2014, 15, 1063-1093.	0.5	739
4	Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation: Cardiovascular Imaging, 2012, 5, 596-603.	1.3	653
5	Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. American Journal of Cardiology, 2011, 107, 1375-1380.	0.7	577
6	Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab. Journal of the American College of Cardiology, 2014, 63, 809-816.	1.2	438
7	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	1.0	406
8	Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. Journal of Clinical Oncology, 2016, 34, 1122-1130.	0.8	376
9	Drugs That May Cause or Exacerbate Heart Failure. Circulation, 2016, 134, e32-69.	1.6	320
10	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2011, 4, 180-187.	1.6	319
11	Heart Failure With Recovered Ejection Fraction. Circulation, 2014, 129, 2380-2387.	1.6	244
12	Cancer Therapyâ€“Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002661.	1.6	241
13	Cancer Therapyâ€“Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies. Journal of the American Heart Association, 2014, 3, e000665.	1.6	221
14	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
15	Cardiovascular Health of Patients WithÂCancer and Cancer Survivors. Journal of the American College of Cardiology, 2015, 65, 2739-2746.	1.2	198
16	Carfilzomib-Associated Cardiovascular Adverse Events. JAMA Oncology, 2018, 4, e174519.	3.4	196
17	Genetic Variants Associated With Cancer Therapyâ€“Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
18	Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1165-1172.	1.2	189

#	Article	IF	Citations
19	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	2.9	184
20	Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circulation: Heart Failure, 2012, 5, 183-190.	1.6	169
21	Detailed Echocardiographic Phenotyping in Breast Cancer Patients. Circulation, 2017, 135, 1397-1412.	1.6	140
22	Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Journal of Clinical Oncology, 2018, 36, 2135-2144.	0.8	139
23	Emerging Paradigms in Cardiomyopathies Associated With Cancer Therapies. Circulation Research, 2013, 113, 754-764.	2.0	132
24	Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1946-1955.	0.8	128
25	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	1.9	127
26	Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma. Journal of Cardiac Failure, 2015, 21, 138-144.	0.7	114
27	Cancer Therapyâ€“Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002843.	1.6	109
28	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology, 2008, 51, 1653-1662.	1.2	104
29	Neuregulin-1Î² Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Circulation, 2009, 120, 310-317.	1.6	103
30	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Journal of the American Heart Association, 2020, 9, e014708.	1.6	94
31	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. Journal of the American College of Cardiology, 2017, 70, 152-162.	1.2	87
32	Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeuticsâ€“Related Cardiac Dysfunction. JACC: Cardiovascular Imaging, 2016, 9, 1131-1141.	2.3	85
33	Comprehensive Assessment ofÂChangesÂin Left Ventricular DiastolicÂFunction With ContemporaryÂBreast Cancer Therapy. JACC: Cardiovascular Imaging, 2020, 13, 198-210.	2.3	79
34	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. Journal of the American College of Cardiology, 2019, 74, 3153-3163.	1.2	78
35	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC: CardioOncology, 2019, 1, 54-65.	1.7	74
36	Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2019, 37, 12-21.	0.8	66

#	Article	IF	Citations
37	The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Journal of the American College of Cardiology, 2011, 58, 386-394.	1.2	65
38	Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart, 2016, 102, 425-430.	1.2	64
39	Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecologic Oncology Research and Practice, 2018, 5, 1.	3.6	62
40	Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. JACC: Cardiovascular Imaging, 2018, 11, 1059-1068.	2.3	61
41	Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. BMJ Open, 2019, 9, e025556.	0.8	60
42	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3601-3609.	3.2	58
43	Preparing the Cardiovascular Workforce to Care for Oncology Patients. Journal of the American College of Cardiology, 2019, 73, 2226-2235.	1.2	56
44	Efficient Quantitative Comparisons of Plasma Proteomes Using Label-Free Analysis with MaxQuant. Methods in Molecular Biology, 2017, 1619, 339-352.	0.4	54
45	Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenetics and Genomics, 2017, 27, 247-254.	0.7	54
46	ST2 and Patient Prognosis in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 64B-69B.	0.7	53
47	Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 103, 851-860.	0.4	53
48	Mechanistic Biomarkers Informative ofÂBoth Cancer and Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 2726-2737.	1.2	51
49	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clinical Cancer Research, 2015, 21, 4048-4054.	3.2	50
50	Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends in Cardiovascular Medicine, 2020, 30, 22-28.	2.3	48
51	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. Journal of Cardiac Failure, 2016, 22, 256-262.	0.7	46
52	FGF23 Modifies the Relationship Between Vitamin D and Cardiac Remodeling. Circulation: Heart Failure, 2013, 6, 817-824.	1.6	44
53	Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. Journal of Gastrointestinal Oncology, 2017, 8, 970-979.	0.6	44
54	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends in Cardiovascular Medicine, 2020, 30, 315-325.	2.3	44

#	Article	IF	Citations
55	Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model. JACC Basic To Translational Science, 2018, 3, 265-276.	1.9	42
56	Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation Research, 2016, 119, 1135-1144.	2.0	40
57	BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC: CardioOncology, 2021, 3, 1-16.	1.7	37
58	Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Network Open, 2021, 4, e210070.	2.8	36
59	Doseâ€“response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial. British Journal of Cancer, 2017, 117, 1614-1620.	2.9	35
60	Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation: Heart Failure, 2018, 11, e004408.	1.6	34
61	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
62	Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clinical Colorectal Cancer, 2018, 17, 32-40.	1.0	32
63	Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. Annual Review of Medicine, 2018, 69, 97-111.	5.0	31
64	Sex Differences in the Incidence of Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S86-93.	0.9	30
65	Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy. Heart Failure Clinics, 2011, 7, 323-331.	1.0	29
66	Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study. Clinical Chemistry, 2019, 65, 1448-1457.	1.5	29
67	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circulation Research, 2022, 130, 632-651.	2.0	29
68	A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance. Clinical Cancer Research, 2021, 27, 2266-2276.	3.2	28
69	Monitoring serum HER2 levels in breast cancer patients. SpringerPlus, 2015, 4, 237.	1.2	27
70	Precision Cardio-Oncology. Journal of Nuclear Medicine, 2019, 60, 443-450.	2.8	27
71	Biomarker Predictors of Cardiac Hospitalization in Chronic Heart Failure: A Recurrent Event Analysis. Journal of Cardiac Failure, 2014, 20, 569-576.	0.7	26
72	A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate. PLoS ONE, 2017, 12, e0169964.	1.1	26

#	Article	IF	Citations
73	Longitudinal Changes in Right Ventricular Function in Tetralogy of Fallot in the Initial Years after Surgical Repair. Journal of the American Society of Echocardiography, 2018, 31, 816-821.	1.2	25
74	Echocardiography Core Laboratory Reproducibility of Cardiac Safety Assessments in Cardio-Oncology. Journal of the American Society of Echocardiography, 2018, 31, 361-371.e3.	1.2	24
75	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). Journal of the American Heart Association, 2015, 4, e002054.	1.6	23
76	Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clinical Breast Cancer, 2019, 19, 259-267.e1.	1.1	22
77	Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. Clinical Colorectal Cancer, 2019, 18, 44-51.	1.0	22
78	Diastolic dysfunction in tetralogy of Fallot: Comparison of echocardiography with catheterization. Echocardiography, 2018, 35, 1641-1648.	0.3	21
79	Cardio-Oncology. JACC Basic To Translational Science, 2021, 6, 705-718.	1.9	21
80	Multimarker Testing With ST2 in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 76B-80B.	0.7	19
81	Acute Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. Journal of the American Society of Echocardiography, 2022, 35, 305-311.	1.2	19
82	Development and evaluation of multi-marker risk scores for clinical prognosis. Statistical Methods in Medical Research, 2016, 25, 255-271.	0.7	18
83	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. JACC: CardioOncology, 2019, 1, 105-113.	1.7	17
84	British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Research and Practice, 2021, 8, G1-G18.	0.6	17
85	COVID-19 Clinical Trials. JACC Basic To Translational Science, 2020, 5, 501-517.	1.9	16
86	Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer, 2021, 127, 458-466.	2.0	16
87	The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clinical Cardiology, 2005, 28, 67-70.	0.7	15
88	Left Ventricular Remodeling in Human Heart Failure: Quantitative Echocardiographic Assessment of 1,794 Patients. Echocardiography, 2012, 29, 758-765.	0.3	15
89	In-Depth, Reproducible Analysis of Human Plasma Using IgY 14 and SuperMix Immunodepletion. Methods in Molecular Biology, 2017, 1619, 81-101.	0.4	14
90	Persistent cardiac dysfunction on echocardiography in African American women with severe preeclampsia. Pregnancy Hypertension, 2019, 17, 127-132.	0.6	14

#	Article	IF	Citations
91	Primer on Biomarker Discovery in Cardio-Oncology. JACC: CardioOncology, 2020, 2, 379-384.	1.7	14
92	Modified Routine Cardiac Imaging Surveillance of Adult Cancer Patients and Survivors During the COVID-19 Pandemic. JACC: CardioOncology, 2020, 2, 345-349.	1.7	14
93	Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients. BMC Sports Science, Medicine and Rehabilitation, 2022, 14, 31.	0.7	14
94	Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 1233-1237.	2.0	13
95	Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction. European Heart Journal Cardiovascular Imaging, 2021, 22, 418-426.	0.5	13
96	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal of the National Cancer Institute, 2021, 113, 513-522.	3.0	13
97	Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, CIR0000000000001032.	1.6	13
98	Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart, 2017, 4, e000524.	0.9	12
99	COVID-19 Clinical Trials. JACC: CardioOncology, 2020, 2, 254-269.	1.7	12
100	Gender Differences in Cardiac Remodeling and Clinical Outcomes in Chronic Stable Angina Pectoris (from the ACTION Trial). American Journal of Cardiology, 2010, 105, 943-947.	0.7	11
101	Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD. Kidney International Reports, 2020, 5, 1052-1060.	0.4	11
102	Racial and Ethnic Disparities in Cancer-Associated Thrombosis. Thrombosis and Haemostasis, 2022, 122, 662-665.	1.8	11
103	Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08â€“10 trial. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986423.	1.4	10
104	Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. Open Heart, 2019, 6, e001025.	0.9	10
105	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. Cancer, 2019, 125, 2762-2771.	2.0	10
106	Twoâ€dimensional speckleâ€tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. Echocardiography, 2019, 36, 2033-2040.	0.3	9
107	Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1301-1310.	0.4	9
108	Damage to cardiac vasculature may be associated with breast cancer treatment-induced cardiotoxicity. Cardio-Oncology, 2021, 7, 15.	0.8	9

#	Article	IF	Citations
109	Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 740.	1.2	9
110	Physical activity during and after breast cancer therapy and associations of baseline physical activity with changes in cardiac function by echocardiography. Cancer Medicine, 2020, 9, 6122-6131.	1.3	8
111	Cardiology Involvement in Patients With Breast Cancer Treated With Trastuzumab. JACC: CardioOncology, 2020, 2, 179-189.	1.7	8
112	Application of an automatic segmentation method for evaluating cardiac structure doses received by breast radiotherapy patients. Physics and Imaging in Radiation Oncology, 2021, 19, 138-144.	1.2	8
113	Quantitative Comparisons of Large Numbers of Human Plasma Samples Using TMT10plex Labeling. Methods in Molecular Biology, 2017, 1619, 319-337.	0.4	7
114	Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 946-952.	0.4	7
115	Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 2282-2289.	0.4	7
116	Priorities in the Cardiovascular Care of Breast Cancer Survivors. Journal of Oncology Practice, 2018, 14, 205-211.	2.5	6
117	Heart Failure Site-Based Research inÂthe United States. JACC: Heart Failure, 2019, 7, 431-438.	1.9	6
118	Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2017, 35, 8018-8018.	0.8	6
119	Cardiac Tamponade as the FirstÂManifestation of Erdheim-Chester Disease. JACC: CardioOncology, 2020, 2, 324-328.	1.7	4
120	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	1.9	4
121	Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 934.e1-934.e6.	0.6	4
122	Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Childrenâ€™s Oncology Group report.. Journal of Clinical Oncology, 2018, 36, 10501-10501.	0.8	3
123	Soluble Flt1 levels are associated with cardiac dysfunction in Black women with and without severe preeclampsia. Hypertension in Pregnancy, 2021, 40, 44-49.	0.5	3
124	The Associations between Peripheral Artery Disease and Physical Outcome Measures in Men and Women with Chronic Kidney Disease. Annals of Vascular Surgery, 2016, 35, 111-120.	0.4	2
125	Resiliency and Our Cardio-Oncology Community. JACC: CardioOncology, 2020, 2, 343-344.	1.7	2
126	Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. JACC Basic To Translational Science, 2022, 7, 1-10.	1.9	2

#	Article	IF	Citations
127	BRCA1/2 Mutations and Cardiovascular Function in Breast Cancer Survivors. Frontiers in Cardiovascular Medicine, 2022, 9, 833171.	1.1	2
128	Cardiovascular toxicities of therapy for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 121-128.	0.8	1
129	Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging study. Cardio-Oncology, 2020, 6, 13.	0.8	1
130	Genetics of Anthracycline-Mediated Cardiotoxicity: Current Status and Challenges. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	1
131	How to Become a Cardio-Oncology Investigator. JACC: CardioOncology, 2021, 3, 170-171.	1.7	1
132	Adding Precision to Defining Bleeding and Ischemic Risk With PCI in CancerÂPatients. JACC: Cardiovascular Interventions, 2021, 14, 1106-1108.	1.1	1
133	Sustained Increases in IGFBP-7 May Be Related to Doxorubicin in Breast Cancer Patients. JACC: CardioOncology, 2021, 3, 444-446.	1.7	1
134	Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e507-e511.	0.3	1
135	A systematic review of randomized controlled trials (RCTs) of exercise interventions using digital activity trackers (E-DAT) in cancer patients.. Journal of Clinical Oncology, 2018, 36, 108-108.	0.8	1
136	Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center wake forest NCORP research-base study.. Journal of Clinical Oncology, 2020, 38, TPS602-TPS602.	0.8	1
137	How to Apply Translational Models to Probe Mechanisms of Cardiotoxicity. JACC: CardioOncology, 2022, 4, 130-135.	1.7	1
138	Continuing Medical Education Activity in Echocardiography. Echocardiography, 2012, 29, 757-757.	0.3	0
139	3173 A Mouse Model to Study Image-Guided, Radiation-Induced Cardiac Injury and Potential Clinically Targetable Biologic Mediators. Journal of Clinical and Translational Science, 2019, 3, 101-101.	0.3	0
140	The Impact of Mentorship. JACC: CardioOncology, 2019, 1, 291-292.	1.7	0
141	Reflections on Our Inaugural Year of JACC: CardioOncology, With Gratitude and Tireless Devotion. JACC: CardioOncology, 2020, 2, 532-534.	1.7	0
142	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1455-1456.	2.3	0
143	Cardio-Oncology and the Patientâ€“Physician Relationship. JACC: CardioOncology, 2020, 2, 146-148.	1.7	0
144	Myocardial perfusion PET imaging to evaluate coronary microvascular dysfunction in men with prostate cancer receiving androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 211-211.	0.8	0

#	Article	IF	Citations
145	JACC: CardioOncology. JACC: CardioOncology, 2021, 3, 465-466.	1.7	0
146	JACC: CardioOncology. Journal of the American College of Cardiology, 2021, 78, 1480-1481.	1.2	0
147	Systemic arterial properties in pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-3.	0.8	0
148	Abstract 13501: Measures of Three-dimensional Left Ventricular Mechanics Deteriorate Acutely After Cardiotoxic Cancer Therapy. Circulation, 2015, 132, .	1.6	0
149	Feasibility of utilizing a novel mhealth platform to deliver an evidence-based exercise intervention among testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2017, 35, e21608-e21608.	0.8	0
150	Serum biomarkers for detection of cardiomyopathy in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.. Journal of Clinical Oncology, 2019, 37, e21526-e21526.	0.8	0
151	Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study.. Journal of Clinical Oncology, 2019, 37, TPS11634-TPS11634.	0.8	0
152	Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study.. Journal of Clinical Oncology, 2019, 37, e19534-e19534.	0.8	0
153	Assessment and management of cardiovascular risk factors among U.S. Veterans with newly diagnosed prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5510-5510.	0.8	0
154	Change in cardiac function with CPX-351 in relapsed pediatric AML: A Childrenâ€™s Oncology Group (COG) report from AAML1421.. Journal of Clinical Oncology, 2020, 38, 10532-10532.	0.8	0
155	A Lift. JACC: CardioOncology, 2020, 2, 822-823.	1.7	0
156	The impact of anthracycline-based chemotherapy on fatigue: Results from WF-97415.. Journal of Clinical Oncology, 2022, 40, e24115-e24115.	0.8	0
157	LVEF decline in relation to body composition among women treated for breast cancer: WF-97415.. Journal of Clinical Oncology, 2022, 40, 10556-10556.	0.8	0
158	Impact of cardiometabolic health and abdominal adipose tissue on physical function in women with breast cancer (WF-97415).. Journal of Clinical Oncology, 2022, 40, e18696-e18696.	0.8	0
159	Association between up-front surgery and risk of stroke in U.S. veterans with oropharyngeal squamous cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 6057-6057.	0.8	0
160	Randomized trial of atorvastatin during and following receipt of doxorubicin for breast cancer and lymphoma (WF-98213).. Journal of Clinical Oncology, 2022, 40, 12072-12072.	0.8	0